BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21917628)

  • 1. Evolution of radiation therapy within the German Hodgkin Study Group trials.
    Eich HT; Kriz J; Müller RP
    J Natl Compr Canc Netw; 2011 Sep; 9(9):1073-80. PubMed ID: 21917628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
    Müller RP; Eich HT
    Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
    Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology].
    Eich HT; Müller RP; Ansén S; Josting A; Engert A; Hansemann K; Pfistner B; Wolf J; Willich N; Diehl V
    Rontgenpraxis; 2003; 55(3):114-24. PubMed ID: 15119314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
    Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemoradiotherapy in early Hodgkin lymphoma.
    André MP
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):33-47. PubMed ID: 24287066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH; Anter AH; Awad IA
    Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
    Eich HT; Gossmann A; Engert A; Kriz J; Bredenfeld H; Hansemann K; Skripnitchenko R; Brillant C; Pfistner B; Staar S; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1187-92. PubMed ID: 17703895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
    J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
    Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
    Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
    Paumier A; Ghalibafian M; Beaudre A; Ferreira I; Pichenot C; Messai T; Lessard NA; Lefkopoulos D; Girinsky T
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):199-205. PubMed ID: 21481723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
    N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma: an analysis of the German Hodgkin Study Group.
    Eich HT; Engenhart-Cabillic R; Hansemann K; Lukas P; Schneeweiss A; Seegenschmiedt H; Skripnitchenko R; Staar S; Willich N; Müller RP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1419-24. PubMed ID: 18234433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Engert A; Diehl V
    Ann Oncol; 2000; 11 Suppl 1():81-5. PubMed ID: 10707785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of early-stage Hodgkin lymphoma.
    Engert A; Raemaekers J
    Semin Hematol; 2016 Jul; 53(3):165-70. PubMed ID: 27496307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.